Physician profile
Jane M Chu
NPI 1700184249
$4,339.96
in general payments reported to CMS, 2019-2025
28 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $955 · 2022: $988 · 2023: $722 · 2024: $1,011 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,396.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $675.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $651.61 | 2021-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.88 | 2022-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $347.49 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Jazz Pharmaceuticals INC. | $291.31 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.61 | 2021-2024 | Jardiance, Synjardy |
| Harmony Biosciences LLC | $243.99 | 2022-2024 | Wakix |
| Lilly USA, LLC | $238.61 | 2021-2025 | Mounjaro, Jardiance, Baqsimi |
| Amgen INC. | $206.60 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $125.86 | 2021-2025 | |
| Novo Nordisk INC | $109.57 | 2024-2025 | Ozempic |
| Corcept Therapeutics | $84.65 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $77.30 | 2021-2024 | Trelegy Ellipta |
| Philips North America LLC | $60.01 | 2024 | (Ak6) Vest Therapy |
| Evoke Pharma, INC. | $59.80 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $55.33 | 2021-2023 | |
| Eisai INC. | $45.85 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.81 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $34.82 | 2023 | Quviviq |
| Shield Therapeutics INC | $33.55 | 2025 | |
| Melinta Therapeutics, LLC | $27.65 | 2021 | |
| Sumitomo Pharma America, INC. | $27.15 | 2025 | Gemtesa |
| Abbott Laboratories | $23.37 | 2023 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $19.61 | 2024 | |
| Ironwood Pharmaceuticals, INC | $17.53 | 2021 | |
| Exact Sciences Corporation | $17.18 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Esperion Therapeutics, INC. | $13.89 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.